US5378696A
(en)
*
|
1990-09-19 |
1995-01-03 |
American Home Products Corporation |
Rapamycin esters
|
US5177203A
(en)
*
|
1992-03-05 |
1993-01-05 |
American Home Products Corporation |
Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
|
GB9221220D0
(en)
*
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
US5434260A
(en)
*
|
1992-10-13 |
1995-07-18 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5489680A
(en)
*
|
1992-10-13 |
1996-02-06 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5480988A
(en)
*
|
1992-10-13 |
1996-01-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5480989A
(en)
*
|
1992-10-13 |
1996-01-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5258389A
(en)
*
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
US5349060A
(en)
*
|
1993-01-07 |
1994-09-20 |
American Home Products Corporation |
Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
|
US5252579A
(en)
*
|
1993-02-16 |
1993-10-12 |
American Home Products Corporation |
Macrocyclic immunomodulators
|
US5310903A
(en)
*
|
1993-03-05 |
1994-05-10 |
Merck & Co., Inc. |
Imidazolidyl rapamycin derivatives
|
US5310901A
(en)
*
|
1993-03-05 |
1994-05-10 |
Merck & Co., Inc. |
O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
|
GB9307491D0
(en)
*
|
1993-04-08 |
1993-06-02 |
Sandoz Ltd |
Organic compounds
|
JPH08509499A
(ja)
|
1993-04-23 |
1996-10-08 |
アボツト・ラボラトリーズ |
ラパマイシン結合体及び抗体
|
US5504091A
(en)
*
|
1993-04-23 |
1996-04-02 |
American Home Products Corporation |
Biotin esters of rapamycin
|
US7279561B1
(en)
|
1993-04-23 |
2007-10-09 |
Wyeth |
Anti-rapamycin monoclonal antibodies
|
CH686761A5
(de)
|
1993-05-27 |
1996-06-28 |
Sandoz Ag |
Galenische Formulierungen.
|
US5387680A
(en)
*
|
1993-08-10 |
1995-02-07 |
American Home Products Corporation |
C-22 ring stabilized rapamycin derivatives
|
US5378836A
(en)
*
|
1993-10-08 |
1995-01-03 |
American Home Products Corporation |
Rapamycin oximes and hydrazones
|
US5373014A
(en)
*
|
1993-10-08 |
1994-12-13 |
American Home Products Corporation |
Rapamycin oximes
|
US5391730A
(en)
*
|
1993-10-08 |
1995-02-21 |
American Home Products Corporation |
Phosphorylcarbamates of rapamycin and oxime derivatives thereof
|
JP4105761B2
(ja)
*
|
1993-11-19 |
2008-06-25 |
アボット・ラボラトリーズ |
ラパミシン(マクロライド)の半合成類似体免疫調節剤
|
US5527907A
(en)
*
|
1993-11-19 |
1996-06-18 |
Abbott Laboratories |
Macrolide immunomodulators
|
US5385910A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Gem-distributed esters of rapamycin
|
US5385908A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Hindered esters of rapamycin
|
US5385909A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Heterocyclic esters of rapamycin
|
WO1995016691A1
(en)
*
|
1993-12-17 |
1995-06-22 |
Sandoz Ltd. |
Rapamycin derivatives useful as immunosuppressants
|
US5389639A
(en)
*
|
1993-12-29 |
1995-02-14 |
American Home Products Company |
Amino alkanoic esters of rapamycin
|
US5525610A
(en)
*
|
1994-03-31 |
1996-06-11 |
American Home Products Corporation |
42-Epi-rapamycin and pharmaceutical compositions thereof
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
US5463048A
(en)
*
|
1994-06-14 |
1995-10-31 |
American Home Products Corporation |
Rapamycin amidino carbamates
|
MY129435A
(en)
|
1994-10-26 |
2007-04-30 |
Novartis Ag |
Pharmaceutical microemulsion preconcentrates
|
US5491231A
(en)
*
|
1994-11-28 |
1996-02-13 |
American Home Products Corporation |
Hindered N-oxide esters of rapamycin
|
US5621108A
(en)
*
|
1994-12-05 |
1997-04-15 |
Trustees Of The University Of Pennsylvania |
Processes and intermediates for preparing macrocycles
|
US5563145A
(en)
*
|
1994-12-07 |
1996-10-08 |
American Home Products Corporation |
Rapamycin 42-oximes and hydroxylamines
|
CA2219659C
(en)
|
1995-06-09 |
2008-03-18 |
Novartis Ag |
Rapamycin derivatives
|
US5780462A
(en)
|
1995-12-27 |
1998-07-14 |
American Home Products Corporation |
Water soluble rapamycin esters
|
US5922730A
(en)
*
|
1996-09-09 |
1999-07-13 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
US20060198867A1
(en)
*
|
1997-09-25 |
2006-09-07 |
Abbott Laboratories, Inc. |
Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
|
US7399480B2
(en)
|
1997-09-26 |
2008-07-15 |
Abbott Laboratories |
Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
|
US6015815A
(en)
*
|
1997-09-26 |
2000-01-18 |
Abbott Laboratories |
Tetrazole-containing rapamycin analogs with shortened half-lives
|
US20030129215A1
(en)
|
1998-09-24 |
2003-07-10 |
T-Ram, Inc. |
Medical devices containing rapamycin analogs
|
US6890546B2
(en)
|
1998-09-24 |
2005-05-10 |
Abbott Laboratories |
Medical devices containing rapamycin analogs
|
US8257726B2
(en)
*
|
1997-09-26 |
2012-09-04 |
Abbott Laboratories |
Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
|
US7357942B2
(en)
*
|
1997-09-26 |
2008-04-15 |
Abbott Laboratories |
Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
|
US8257725B2
(en)
*
|
1997-09-26 |
2012-09-04 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
US8394398B2
(en)
*
|
1997-09-26 |
2013-03-12 |
Abbott Laboratories |
Methods of administering rapamycin analogs with anti-inflammatories using medical devices
|
US8057816B2
(en)
*
|
1997-09-26 |
2011-11-15 |
Abbott Laboratories |
Compositions and methods of administering paclitaxel with other drugs using medical devices
|
US7378105B2
(en)
*
|
1997-09-26 |
2008-05-27 |
Abbott Laboratories |
Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
|
US20030216303A1
(en)
*
|
1998-03-06 |
2003-11-20 |
Michael Ambuhl |
Emulsion preconcentrates containing cyclosporin or a macrolide
|
US6015809A
(en)
*
|
1998-08-17 |
2000-01-18 |
American Home Products Corporation |
Photocyclized rapamycin
|
US20060240070A1
(en)
*
|
1998-09-24 |
2006-10-26 |
Cromack Keith R |
Delivery of highly lipophilic agents via medical devices
|
US7455853B2
(en)
*
|
1998-09-24 |
2008-11-25 |
Abbott Cardiovascular Systems Inc. |
Medical devices containing rapamycin analogs
|
US8257724B2
(en)
*
|
1998-09-24 |
2012-09-04 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
US7960405B2
(en)
*
|
1998-09-24 |
2011-06-14 |
Abbott Laboratories |
Compounds and methods for treatment and prevention of diseases
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
US6331547B1
(en)
|
1999-08-18 |
2001-12-18 |
American Home Products Corporation |
Water soluble SDZ RAD esters
|
US20070032853A1
(en)
|
2002-03-27 |
2007-02-08 |
Hossainy Syed F |
40-O-(2-hydroxy)ethyl-rapamycin coated stent
|
US7807211B2
(en)
|
1999-09-03 |
2010-10-05 |
Advanced Cardiovascular Systems, Inc. |
Thermal treatment of an implantable medical device
|
US6790228B2
(en)
*
|
1999-12-23 |
2004-09-14 |
Advanced Cardiovascular Systems, Inc. |
Coating for implantable devices and a method of forming the same
|
TWI256395B
(en)
*
|
1999-09-29 |
2006-06-11 |
Wyeth Corp |
Regioselective synthesis of rapamycin derivatives
|
US6277983B1
(en)
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
GB0008785D0
(en)
|
2000-04-10 |
2000-05-31 |
Novartis Ag |
Organic compounds
|
US6670355B2
(en)
*
|
2000-06-16 |
2003-12-30 |
Wyeth |
Method of treating cardiovascular disease
|
ES2228932T3
(es)
|
2000-08-11 |
2005-04-16 |
Wyeth |
Procedimiento de tratamiento del carcinoma positivo de estrogenos.
|
DK1319008T3
(da)
|
2000-09-19 |
2009-02-09 |
Wyeth Corp |
Vandoplöselige rapamycinestere
|
US6399625B1
(en)
|
2000-09-27 |
2002-06-04 |
Wyeth |
1-oxorapamycins
|
US6440991B1
(en)
|
2000-10-02 |
2002-08-27 |
Wyeth |
Ethers of 7-desmethlrapamycin
|
US6399626B1
(en)
|
2000-10-02 |
2002-06-04 |
Wyeth |
Hydroxyesters of 7-desmethylrapamycin
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20080145402A1
(en)
*
|
2001-09-10 |
2008-06-19 |
Abbott Cardiovascular Systems Inc. |
Medical Devices Containing Rapamycin Analogs
|
US6939376B2
(en)
*
|
2001-11-05 |
2005-09-06 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US7682387B2
(en)
|
2002-04-24 |
2010-03-23 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
EP1478358B1
(en)
|
2002-02-11 |
2013-07-03 |
Bayer HealthCare LLC |
Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
|
US20040024450A1
(en)
*
|
2002-04-24 |
2004-02-05 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
ATE385795T1
(de)
|
2002-07-30 |
2008-03-15 |
Wyeth Corp |
Parenterale formulierungen mit einem rapamycin hydroxyester
|
EP1536850B1
(en)
|
2002-09-06 |
2016-08-10 |
Abbott Laboratories |
Medical device having hydration inhibitor
|
AU2003293529A1
(en)
*
|
2002-12-16 |
2004-07-29 |
Nitromed, Inc. |
Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
|
DK1592457T3
(da)
*
|
2003-01-27 |
2012-10-22 |
Endocyte Inc |
Folat-vinblastin-konjugat som lægemiddel
|
UY28213A1
(es)
|
2003-02-28 |
2004-09-30 |
Bayer Pharmaceuticals Corp |
Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
|
CA2526636C
(en)
|
2003-05-20 |
2012-10-02 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas for diseases mediated by pdgfr
|
US20050118344A1
(en)
|
2003-12-01 |
2005-06-02 |
Pacetti Stephen D. |
Temperature controlled crimping
|
CL2004001834A1
(es)
*
|
2003-07-23 |
2005-06-03 |
Bayer Pharmaceuticals Corp |
Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
|
CA2539324A1
(en)
*
|
2003-09-18 |
2005-03-31 |
Macusight, Inc. |
Transscleral delivery
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US7220755B2
(en)
*
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
WO2005089855A1
(en)
*
|
2004-03-19 |
2005-09-29 |
Abbott Laboratories |
Multiple drug delivery from a balloon and a prosthesis
|
US20100030183A1
(en)
*
|
2004-03-19 |
2010-02-04 |
Toner John L |
Method of treating vascular disease at a bifurcated vessel using a coated balloon
|
US20070027523A1
(en)
*
|
2004-03-19 |
2007-02-01 |
Toner John L |
Method of treating vascular disease at a bifurcated vessel using coated balloon
|
US8431145B2
(en)
*
|
2004-03-19 |
2013-04-30 |
Abbott Laboratories |
Multiple drug delivery from a balloon and a prosthesis
|
JP2007532655A
(ja)
*
|
2004-04-14 |
2007-11-15 |
ワイス |
ラパマイシンコンジュゲートおよび抗体のための前駆体である、ジカルボン酸とのラパマイシン42−エステルおよびジカルボン酸とのfk−50632−エステルの調製プロセス
|
EP1740710A1
(en)
*
|
2004-04-27 |
2007-01-10 |
Wyeth |
Labeling of rapamycin using rapamycin-specific methylases
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
AU2005326322B2
(en)
*
|
2004-07-01 |
2009-02-05 |
Yale University |
Targeted and high density drug loaded polymeric materials
|
JP5149620B2
(ja)
|
2004-07-23 |
2013-02-20 |
エンドサイト,インコーポレイテッド |
2価リンカーおよびその結合体
|
US7901451B2
(en)
*
|
2004-09-24 |
2011-03-08 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
WO2006041942A2
(en)
*
|
2004-10-04 |
2006-04-20 |
Qlt Usa, Inc. |
Ocular delivery of polymeric delivery formulations
|
US8313763B2
(en)
*
|
2004-10-04 |
2012-11-20 |
Tolmar Therapeutics, Inc. |
Sustained delivery formulations of rapamycin compounds
|
WO2006050461A1
(en)
*
|
2004-10-28 |
2006-05-11 |
Wyeth |
Use of an mtor inhibitor in treatment of uterine leiomyoma
|
US8663639B2
(en)
*
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
US20060257450A1
(en)
*
|
2005-03-21 |
2006-11-16 |
Sreenivasu Mudumba |
Drug delivery systems for treatment of diseases or conditions
|
BRPI0608152A2
(pt)
|
2005-02-09 |
2009-11-10 |
Macusight Inc |
formulações para tratamento ocular
|
GB0503936D0
(en)
|
2005-02-25 |
2005-04-06 |
San Raffaele Centro Fond |
Method
|
US8044200B2
(en)
*
|
2005-03-16 |
2011-10-25 |
Endocyte, Inc. |
Synthesis and purification of pteroic acid and conjugates thereof
|
EP1868663B1
(en)
*
|
2005-03-23 |
2011-11-16 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
JP5242374B2
(ja)
|
2005-03-23 |
2013-07-24 |
アボット・ラボラトリーズ |
組成物ならびに長期効力を得るための医療機器を用いたラパマイシン類縁体の投与方法
|
EP1886138A4
(en)
*
|
2005-05-11 |
2009-04-15 |
Genetic Technologies Ltd |
PROCESS FOR ENRICHING FETTAL CELLS
|
MX2008000897A
(es)
|
2005-07-20 |
2008-03-18 |
Novartis Ag |
Combinacion de una pirimidil-amino-benzamida y un inhibidor de cinasa mtor.
|
EP1912675B1
(en)
|
2005-07-25 |
2014-02-12 |
Emergent Product Development Seattle, LLC |
B-cell reduction using cd37-specific and cd20-specific binding molecules
|
AU2006279304A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Endocyte, Inc. |
Multi-drug ligand conjugates
|
CN103110948A
(zh)
|
2005-11-04 |
2013-05-22 |
惠氏公司 |
mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
|
ZA200804550B
(en)
|
2005-11-09 |
2009-08-26 |
Combinatorx Inc |
Methods, compositions, and kits for the treatment of medical conditions
|
US7700614B2
(en)
*
|
2005-12-14 |
2010-04-20 |
Abbott Laboratories |
One pot synthesis of tetrazole derivatives of rapamycin
|
EP1962819A1
(en)
*
|
2005-12-20 |
2008-09-03 |
Wyeth |
Control of cci-779 dosage form stability through control of drug substance impurities
|
US20070196850A1
(en)
*
|
2006-01-27 |
2007-08-23 |
University Of Washington |
Identification of aging genes through large-scale analysis
|
CA2635797C
(en)
*
|
2006-02-09 |
2015-03-31 |
Macusight, Inc. |
Stable formulations, and methods of their preparation and use
|
US7622477B2
(en)
*
|
2006-02-28 |
2009-11-24 |
Cordis Corporation |
Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
|
US7678901B2
(en)
*
|
2006-02-28 |
2010-03-16 |
Wyeth |
Rapamycin analogs containing an antioxidant moiety
|
WO2007112052A2
(en)
*
|
2006-03-23 |
2007-10-04 |
Macusight, Inc. |
Formulations and methods for vascular permeability-related diseases or conditions
|
US7883855B2
(en)
*
|
2006-07-21 |
2011-02-08 |
Abbott Laboratories |
Immunosuppressant drug extraction reagent for immunoassays
|
US20080051691A1
(en)
*
|
2006-08-28 |
2008-02-28 |
Wyeth |
Implantable shunt or catheter enabling gradual delivery of therapeutic agents
|
WO2008033956A2
(en)
|
2006-09-13 |
2008-03-20 |
Elixir Medical Corporation |
Macrocyclic lactone compounds and methods for their use
|
EP2077819A4
(en)
|
2006-09-28 |
2011-05-25 |
Follica Inc |
METHODS, MATERIALS, AND COMPOSITIONS FOR GENERATING NEW CELLULAR FOLLICLES AND PUSHING HAIR
|
US8067055B2
(en)
*
|
2006-10-20 |
2011-11-29 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method of use
|
US20080097591A1
(en)
|
2006-10-20 |
2008-04-24 |
Biosensors International Group |
Drug-delivery endovascular stent and method of use
|
US20080103584A1
(en)
*
|
2006-10-25 |
2008-05-01 |
Biosensors International Group |
Temporal Intraluminal Stent, Methods of Making and Using
|
US9737640B2
(en)
|
2006-11-20 |
2017-08-22 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US9700704B2
(en)
|
2006-11-20 |
2017-07-11 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US8414910B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8430055B2
(en)
|
2008-08-29 |
2013-04-30 |
Lutonix, Inc. |
Methods and apparatuses for coating balloon catheters
|
US8414525B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8414526B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
|
US8998846B2
(en)
|
2006-11-20 |
2015-04-07 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US8425459B2
(en)
|
2006-11-20 |
2013-04-23 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
|
US8414909B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US20080276935A1
(en)
|
2006-11-20 |
2008-11-13 |
Lixiao Wang |
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
|
US10265407B2
(en)
|
2007-02-15 |
2019-04-23 |
Yale University |
Modular nanodevices for smart adaptable vaccines
|
WO2008101231A2
(en)
|
2007-02-16 |
2008-08-21 |
Endocyte, Inc. |
Methods and compositions for treating and diagnosing kidney disease
|
US20100151436A1
(en)
*
|
2007-03-02 |
2010-06-17 |
Fong Peter M |
Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles
|
WO2008112873A2
(en)
|
2007-03-14 |
2008-09-18 |
Endocyte, Inc. |
Binding ligand linked drug delivery conjugates of tubulysins
|
TW200901989A
(en)
|
2007-04-10 |
2009-01-16 |
Wyeth Corp |
Anti-tumor activity of CCI-779 in papillary renal cell cancer
|
JP2008305262A
(ja)
*
|
2007-06-08 |
2008-12-18 |
Konica Minolta Business Technologies Inc |
サーバ及びシンクライアント環境でのプリンタ紹介方法
|
US9877965B2
(en)
|
2007-06-25 |
2018-01-30 |
Endocyte, Inc. |
Vitamin receptor drug delivery conjugates for treating inflammation
|
CN104383553A
(zh)
|
2007-06-25 |
2015-03-04 |
恩多塞特公司 |
含有亲水性间隔区接头的共轭物
|
US20090148447A1
(en)
*
|
2007-07-06 |
2009-06-11 |
Trubion Pharmaceuticals, Inc. |
Binding Peptides Having a C-terminally Disposed Specific Binding Domain
|
KR100930167B1
(ko)
*
|
2007-09-19 |
2009-12-07 |
삼성전기주식회사 |
초광각 광학계
|
JP5134692B2
(ja)
|
2007-12-19 |
2013-01-30 |
アボット・ラボラトリーズ |
免疫アッセイのための免疫抑制剤薬剤抽出試薬
|
US20100048524A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
EP2278966B1
(en)
*
|
2008-03-21 |
2019-10-09 |
The University of Chicago |
Treatment with opioid antagonists and mtor inhibitors
|
JP6013733B2
(ja)
|
2008-04-11 |
2016-10-25 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
Cd37免疫治療薬および二機能性化学療法薬とのその組合せ
|
WO2010021681A2
(en)
*
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
JP2012504654A
(ja)
*
|
2008-10-03 |
2012-02-23 |
エリクシアー メディカル コーポレイション |
多環状ラクトン化合物およびその使用方法
|
US20120064143A1
(en)
|
2008-11-11 |
2012-03-15 |
The Board Of Regents Of The University Of Texas System |
Inhibition of mammalian target of rapamycin
|
AU2010210422A1
(en)
|
2009-02-05 |
2011-08-18 |
Tokai Pharmaceuticals, Inc. |
Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
|
JP2013509444A
(ja)
|
2009-10-30 |
2013-03-14 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
がんの治療方法及び治療用組成物
|
US10391059B2
(en)
|
2009-11-11 |
2019-08-27 |
Rapamycin Holdings, Inc. |
Oral rapamycin nanoparticle preparations and use
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
US20110130711A1
(en)
*
|
2009-11-19 |
2011-06-02 |
Follica, Inc. |
Hair growth treatment
|
US20110144577A1
(en)
*
|
2009-12-11 |
2011-06-16 |
John Stankus |
Hydrophilic coatings with tunable composition for drug coated balloon
|
US8951595B2
(en)
*
|
2009-12-11 |
2015-02-10 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable molecular architecture for drug-coated balloon
|
US8480620B2
(en)
*
|
2009-12-11 |
2013-07-09 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable solubility profile for drug-coated balloon
|
US20130195919A1
(en)
|
2010-03-05 |
2013-08-01 |
President And Fellows Of Harvard College |
Induced dendritic cell compositions and uses thereof
|
EP2558092B1
(en)
|
2010-04-13 |
2018-06-27 |
Novartis AG |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
|
WO2011128405A1
(en)
|
2010-04-16 |
2011-10-20 |
Novartis Ag |
Combination of organic compounds
|
MX342590B
(es)
|
2010-04-27 |
2016-10-05 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
|
KR101253399B1
(ko)
|
2010-10-26 |
2013-04-11 |
영남대학교 산학협력단 |
아포지단백질 a-i 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
|
EP2683406B1
(en)
|
2011-03-11 |
2019-05-08 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-cd40 antibodies and uses thereof
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
AU2012250010A1
(en)
|
2011-04-25 |
2013-10-10 |
Novartis Ag |
Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
|
EP2532740A1
(en)
|
2011-06-11 |
2012-12-12 |
Michael Schmück |
Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
|
WO2013013708A1
(en)
|
2011-07-26 |
2013-01-31 |
Fundació Institut D'investigació Biomèdica De Bellvitge |
Treatment of acute rejection in renal transplant
|
US10080805B2
(en)
|
2012-02-24 |
2018-09-25 |
Purdue Research Foundation |
Cholecystokinin B receptor targeting for imaging and therapy
|
US20140080175A1
(en)
|
2012-03-29 |
2014-03-20 |
Endocyte, Inc. |
Processes for preparing tubulysin derivatives and conjugates thereof
|
EP2841098A4
(en)
|
2012-04-23 |
2016-03-02 |
Allertein Therapeutics Llc |
NANOPARTICLES FOR THE TREATMENT OF ALLERGIES
|
ES2574522T3
(es)
|
2012-06-08 |
2016-06-20 |
Biotronik Ag |
Ésteres 40-O-hidrocarburo cíclico de rapamicina, composiciones y procedimientos
|
WO2013192367A1
(en)
|
2012-06-22 |
2013-12-27 |
Novartis Ag |
Neuroendocrine tumor treatment
|
US9750728B2
(en)
|
2012-09-29 |
2017-09-05 |
Targeted Therapeutics, Llc |
Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
|
CN103705925B
(zh)
|
2012-09-29 |
2018-03-30 |
段磊 |
抑制PI3K/AKT/mTOR信号通路的药物组合
|
WO2014059295A1
(en)
|
2012-10-12 |
2014-04-17 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors to treat vascular cognitive impairment
|
BR112015008365A2
(pt)
|
2012-10-16 |
2017-07-04 |
Endocyte Inc |
composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
|
EP2914260A1
(en)
|
2012-10-31 |
2015-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
EP2919759A4
(en)
|
2012-11-14 |
2016-07-20 |
Ohio State Innovation Foundation |
MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
|
US20160030401A1
(en)
|
2013-03-13 |
2016-02-04 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
|
EP4066841A1
(en)
|
2013-03-14 |
2022-10-05 |
University of Maryland, Baltimore |
Androgen receptor down-regulating agents and uses thereof
|
EP2981285B1
(en)
|
2013-04-03 |
2020-06-03 |
N-Fold Llc |
Novel nanoparticle compositions
|
SG11201600525XA
(en)
|
2013-08-12 |
2016-02-26 |
Tokai Pharmaceuticals Inc |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
KR20160110963A
(ko)
|
2014-02-11 |
2016-09-23 |
노파르티스 아게 |
암 치료를 위한 pi3k 억제제를 포함하는 제약 조합물
|
AU2015237200A1
(en)
|
2014-03-27 |
2016-10-06 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
EP3131546B1
(en)
|
2014-04-16 |
2022-02-16 |
Rapamycin Holdings, Inc. |
Oral rapamycin preparation for use in treating feline chronic gingivo- stomatitis (fcgs)
|
WO2015171723A1
(en)
|
2014-05-06 |
2015-11-12 |
Research Development Foundation |
Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
|
MX2016015569A
(es)
|
2014-06-02 |
2017-04-25 |
Children´S Medical Center Corp |
Metodos y composiciones para inmunomodulacion.
|
CN107073066B
(zh)
|
2014-09-11 |
2021-09-17 |
加利福尼亚大学董事会 |
mTORC1抑制剂
|
US10479807B2
(en)
|
2014-10-08 |
2019-11-19 |
Epigenetics Phrama LLC |
Silylated pyrimidine prodrugs and methods of their use
|
WO2017029391A1
(en)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cancer
|
SI3307322T1
(sl)
|
2015-09-04 |
2021-08-31 |
Primatope Therapeutics Inc. |
Humanizirana protitelesa proti CD40 in njihove uporabe
|
US10682340B2
(en)
|
2016-06-30 |
2020-06-16 |
Durect Corporation |
Depot formulations
|
US10668011B2
(en)
|
2016-06-30 |
2020-06-02 |
Durect Corporation |
Depot formulations
|
RS62456B1
(sr)
|
2016-12-22 |
2021-11-30 |
Amgen Inc |
Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva
|
EA201990127A1
(ru)
|
2016-12-30 |
2020-08-18 |
Дьюрект Корпорейшн |
Депо-препарат
|
EP3576736A4
(en)
|
2017-02-10 |
2020-08-26 |
Torcept Therapeutics Inc. |
RAPAMYCIN ANALOGUE
|
ES2871499T3
(es)
|
2017-05-15 |
2021-10-29 |
Bard Inc C R |
Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
EP3644997A1
(en)
|
2017-06-26 |
2020-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of olmsted syndrome
|
JP2020527044A
(ja)
|
2017-07-13 |
2020-09-03 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
CD8+CD45RCLOW/−Treg集団の拡大増殖および免疫抑制能力を高めるための方法
|
CA3075046A1
(en)
|
2017-09-08 |
2019-03-14 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
AR112834A1
(es)
|
2017-09-26 |
2019-12-18 |
Novartis Ag |
Derivados de rapamicina
|
JP7381492B2
(ja)
|
2018-05-01 |
2023-11-15 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Mtor阻害剤としてのc26-連結ラパマイシン類似体
|
AU2019262978B2
(en)
|
2018-05-01 |
2023-07-13 |
Revolution Medicines, Inc. |
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
|
MA52496A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
MA52501A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
WO2019217691A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
JP7360396B2
(ja)
|
2018-06-01 |
2023-10-12 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤及び同一物の使用方法
|
JP7357644B2
(ja)
|
2018-06-11 |
2023-10-06 |
アムジエン・インコーポレーテツド |
がんを処置するためのkras g12c阻害剤
|
WO2020050890A2
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CA3107352A1
(en)
|
2018-07-23 |
2020-01-30 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
JP2022510573A
(ja)
|
2018-07-23 |
2022-01-27 |
エンクリアー セラピーズ, インク. |
神経障害の治療方法
|
WO2020053125A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
US11541152B2
(en)
|
2018-11-14 |
2023-01-03 |
Lutonix, Inc. |
Medical device with drug-eluting coating on modified device surface
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
WO2020106640A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
TWI844602B
(zh)
|
2018-12-20 |
2024-06-11 |
美商安進公司 |
Kif18a抑制劑
|
EP3898592A1
(en)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
WO2020132649A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
CA3123042A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
AU2020232616A1
(en)
|
2019-03-01 |
2021-09-09 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
WO2020180768A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
US20220176084A1
(en)
|
2019-04-08 |
2022-06-09 |
Bard Peripheral Vascular, Inc. |
Medical device with drug-eluting coating on modified device surface
|
WO2020210634A1
(en)
|
2019-04-11 |
2020-10-15 |
Enclear Therapies, Inc. |
Methods of amelioration of cerebrospinal fluid and devices and systems therefor
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
MX2021014126A
(es)
|
2019-05-21 |
2022-01-04 |
Amgen Inc |
Formas en estado solido.
|
MX2022001296A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
JP2022542967A
(ja)
|
2019-08-02 |
2022-10-07 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
JP2022542394A
(ja)
|
2019-08-02 |
2022-10-03 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
AU2020325115A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
Pyridine derivatives as KIF18A inhibitors
|
WO2021055728A1
(en)
|
2019-09-18 |
2021-03-25 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
JP7340100B2
(ja)
|
2019-10-28 |
2023-09-06 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Kras g12c変異型の小分子阻害薬
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
TW202132314A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
TW202132316A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
CR20220240A
(es)
|
2019-11-04 |
2022-08-03 |
Revolution Medicines Inc |
Inhibidores de ras
|
CN114901662A
(zh)
|
2019-11-08 |
2022-08-12 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
BR112022009390A2
(pt)
|
2019-11-14 |
2022-08-09 |
Amgen Inc |
Síntese melhorada de composto inibidor de kras g12c
|
US20230192682A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
IL294484A
(en)
|
2020-01-07 |
2022-09-01 |
Revolution Medicines Inc |
Dosage for shp2 inhibitor and methods for treating cancer
|
US20230181536A1
(en)
|
2020-04-24 |
2023-06-15 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
EP4139299A1
(en)
|
2020-04-24 |
2023-03-01 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
AU2021308045B2
(en)
|
2020-07-15 |
2024-06-20 |
Taiho Pharmaceutical Co., Ltd. |
Pyrimidine compound-containing combination to be used in tumor treatment
|
CA3187757A1
(en)
|
2020-09-03 |
2022-03-24 |
Ethan AHLER |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
TW202227460A
(zh)
|
2020-09-15 |
2022-07-16 |
美商銳新醫藥公司 |
Ras抑制劑
|
JP2024501280A
(ja)
|
2020-12-22 |
2024-01-11 |
キル・レガー・セラピューティクス・インコーポレーテッド |
Sos1阻害剤およびその使用
|
TW202309053A
(zh)
|
2021-05-05 |
2023-03-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ras阻害剤及びその使用
|
CR20230570A
(es)
|
2021-05-05 |
2024-01-22 |
Revolution Medicines Inc |
Inhibidores de ras
|
JP2024521979A
(ja)
|
2021-05-28 |
2024-06-04 |
大鵬薬品工業株式会社 |
Kras変異タンパク質の小分子阻害剤関連出願の相互参照
|
WO2023288046A1
(en)
|
2021-07-15 |
2023-01-19 |
President And Fellows Of Harvard College |
Compositions and methods relating to cells with adhered particles
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|